TAGRISSO™▼ (osimertinib)
TAGRISSO is an EGFR TKI indicated as a monotherapy for:
- the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations
- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutations-positive (NSCLC).1
Contact AstraZeneca
GB-20649 November 2020
Thank you for visiting the AstraZeneca Medicines website
This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.
Do you wish to continue?
Thank you for visiting the AstraZeneca Medicines website
This link will take you to a website not owned by AstraZeneca. AstraZeneca provides this link as a service to our site visitors. AstraZeneca are not responsible for the content or privacy / legal policies of any third party websites.
Do you wish to continue?
Validating...
Welcome to AstraZeneca Medicines UK
The content on this website is intended for UK Healthcare Professionals only. The website contains both promotional and non-promotional content.
Welcome to the AstraZeneca Medicines Site
Sorry, your web browser is not supported
Unfortunately, you are using an unsupported browser. Please use Google Chrome 52.0 or Internet Explorer 11 or later. Apologies for any inconvenience.
GB-6911 - June 2017